$REGN has been mentioned 13 times over the past 12 months by two distinct FinTwit voices: @adamfeuerstein and @jacobplieth, each contributing 11 mentions. The stock entered this archive on September 4, 2025, with the most recent discussion occurring on May 18, 2026. The biotech category dominated conversation about Regeneron Pharmaceuticals during this period.

@adamfeuerstein's recent posts present contrasting views on $REGN's developments. In late April 2026, the voice noted FDA approval of a gene therapy for OTOF-related hearing loss—a condition affecting approximately 50 newborns annually—with the company providing the treatment at no cost, while questioning potential industry precedent implications. However, more recent commentary expressed significant concern about company performance, with posts from May 2026 characterizing $REGN's behavior and clinical outcomes unfavorably.